Midicial herbal compound for prevention and treatment of diabetes

A composition and hypoglycemic technology, applied in the herbal composition for preventing or treating diabetes, in the field of preventing or treating diabetes, can solve problems such as rising cardiovascular mortality

Inactive Publication Date: 2003-12-17
HOLOMED PHARMA
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Major side effects of biguanides are lactic a

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Midicial herbal compound for prevention and treatment of diabetes
  • Midicial herbal compound for prevention and treatment of diabetes
  • Midicial herbal compound for prevention and treatment of diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0110] Example 1-Materials and Methods-Extraction of Medicinal Plants

[0111] Palm tree is grown in India; the inside of the trunk is collected and dried. Mulberry is grown in Korea and northern China; leaves and roots are collected and dried. Chicken feet ginseng is grown in Vietnam; the whole plant, including roots, branches and leaves, is collected and dried. Ophiopogon japonicus, double-petal rose (Rosa rugosa var typica (Regel)), 栝lou (Maxim) and Zhimu (Bunge) are planted in South Korea and northern China; the roots are collected and dried. Dayflower (L.) is grown in Korea and China; leaves, stems, and flowers are collected and dried. The dry ingredients are ground into powder and mixed (palmwood (about 20%), chicken feet ginseng (about 20%), mulberry (about 15%), Ophiopogon japonicus (about 10%), 栝lou (about 10%), Anemarrhena (about 10%), rose (about 8%) and dayflower (about 7%) w / w). Boil 40g of the combined plant powder and 200ml of water in a slow cooker until the volume...

Embodiment 2

[0112] Example 2-Goto-Kakizaki (GK) rats

[0113] GK rats (Goto Y et al., spontaneous diabetes produced by selective feeding of normal Wistar rats, Proc. Japan. Acad. 51: 80-85, 1975; Sugiyama Y et al., hypoglycemia in spontaneous diabetic GK rats The role of insulin sensitivity in the liver, J.Japan.Diab.Soc., 32:593-599, 1989) is one of the best animals to study NIDDM, because most of these animals develop diabetes at about 3 months of age, and diabetes Symptoms share many pathological features with human NIDDM. GK rats show impaired insulin secretion and peripheral insulin resistance. The insulin response, sensitivity of glycogen synthesis, adipogenesis and DNA synthesis in the liver cells of GK rats were significantly decreased compared with control rats without diabetes. In GK rats, the structure of the islets is destroyed, and obvious fibrotic areas can be seen in the matrix. As the disease progressed, β-cell degranulation was observed, but lymphocyte infiltration of pancrea...

Embodiment 3

[0114] Example 3-Administration of MHCTD to GK rats

[0115] In order to study the control of MHCTD on blood sugar in diabetic GK rats, 3-month-old rats were treated with the above-prepared MHCTD for 5 months. Animals were gavaged with 2.5ml (5g / kg body weight) every day (10 am). GK rats of age and sex matched with water tube were used as controls. Use One Touch glucose meter to measure blood glucose level every week until 1 year old.

[0116] In order to study the effect of MHCTD on the prevention of diabetes, GK rats were treated with MHCTD from 3 weeks of age before the onset of NIDDM. The rats were gavaged with MHCTD (5g / kg body weight) or water every day until 13 weeks of age, and blood glucose levels were measured every week until 13 weeks of age.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention is directed to a herbal medicinal composition for preventing or treating type II diabetes. The composition is comprised of extracts from Pterocarpus marsupium, Morus alba, Orthosiphon aristatus, Opiophogon japonicus, Rosa rugosa, Commelina communis, Trichosanthis kirilowii and Anemarrhena asphodeloides.

Description

Invention field [0001] The present invention relates to a herbal composition for preventing or treating diabetes. The present invention also relates to a method of preventing or treating diabetes by administering the composition to an individual. Background of the invention [0002] Diabetes is a common serious disease characterized by high blood sugar. The disease can be divided into two major categories: insulin-dependent diabetes mellitus (IDDM), also known as type I diabetes, and non-insulin-dependent diabetes mellitus (NIDDM), also known as type II diabetes (World Health Organization Research Group, Diabetes, WHO Tech.Rep.Ser.727:1-113, 1985). IDDM is caused by the lack of insulin caused by cell-mediated autoimmune destruction of pancreatic β cells, and usually occurs in childhood (Yoon JW, Insulin-dependent diabetes mellitus, in Roitt IM and DelvesPJ (eds), "Encyclopedia of Immunology" (Encyclopedia of Immunology), Second Edition, Academic Press Ltd., London, pp.1390-1398; ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4415A61K31/455A61K31/714A61K33/24A61K33/30A61K33/32A61K36/00A61K36/185A61K36/254A61K36/28A61K36/41A61K36/428A61K36/45A61K36/48A61K36/53A61K36/605A61K36/738A61K36/79A61K36/88A61K36/8962A61K36/8964A61K36/8968A61P3/10A61P43/00
CPCY10S514/866A61K36/254A61K36/48A61K36/53A61K36/605A61K36/738A61K36/8962A61K33/32A61K36/8964A61K36/428A61K36/88A61K36/185A61K36/8968A61K33/24A61K31/455A61K31/4415A61K36/45A61K36/28A61K33/30A61K36/79A61K36/41A61P43/00A61P3/10A61K2300/00
Inventor 尹址洹全喜淑
Owner HOLOMED PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap